Linda Mileshkin

CCNE1 Amplification as a Therapeutic Target.

George Au-Yeung, Linda Mileshkin, David DL Bowtell

Journal article  |  2023  |  J Clin Oncol

Australian Genomics: Outcomes of a 5-year national program to accelerate the integration of genomics in healthcare.

Zornitza Stark, Tiffany Boughtwood, Matilda Haas, Jeffrey Braithwaite, Clara L Gaff, Ilias Goranitis, Amanda B Spurdle, David P Hansen, Oliver Hofmann, Nigel Laing, Sylvia Metcalfe, Ainsley J Newson, Hamish S Scott, Natalie Thorne, Robyn L Ward, Marcel E Dinger, Stephanie Best, Janet C Long, Sean M Grimmond, John Pearson, et al.

Journal article  |  2023  |  Am J Hum Genet

Australian Genomics is a national collaborative partnership of more than 100 organizations piloting a whole-of-system approach to ..

Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer.

Nikki L Burdett, Madelynne O Willis, Kathryn Alsop, Allison L Hunt, Ahwan Pandey, Phineas T Hamilton, Tamara Abulez, Xuan Liu, Therese Hoang, Stuart Craig, Sian Fereday, Joy Hendley, Dale W Garsed, Katy Milne, Shreena Kalaria, Ashley Marshall, Brian L Hood, Katlin N Wilson, Kelly A Conrads, Kathleen I Pishas, et al.

Journal article  |  2023  |  Nat Genet

High-grade serous ovarian cancer (HGSC) is frequently characterized by homologous recombination (HR) DNA repair deficiency and, wh..

Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

A Krämer, T Bochtler, C Pauli, G Baciarello, S Delorme, K Hemminki, L Mileshkin, H Moch, K Oien, T Olivier, A Patrikidou, H Wasan, G Zarkavelis, G Pentheroudakis, K Fizazi, undefined ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org

Journal article  |  2023  |  Ann Oncol

A qualitative study of patients with Cancer of Unknown Primary: Perceptions of communication, understanding of diagnosis and genomic testing, and information needs

Kamil Wolyniec, Clare O'Callaghan, Krista Fisher, Sharp Jessica, Richard WW Tothill, David Bowtell, Mileshkin Linda, Penelope Schofield

Journal article  |  2023  |  PSYCHO-ONCOLOGY

OBJECTIVE: Patients with Cancer of Unknown Primary (CUP) commonly report poor understanding of their illness and high levels of ps..

Interpretable deep learning model to predict the molecular classification of endometrial cancer from haematoxylin and eosin-stained whole-slide images: a combined analysis of the PORTEC randomised trials and clinical cohorts.

Sarah Fremond, Sonali Andani, Jurriaan Barkey Wolf, Jouke Dijkstra, Sinéad Melsbach, Jan J Jobsen, Mariel Brinkhuis, Suzan Roothaan, Ina Jurgenliemk-Schulz, Ludy CHW Lutgens, Remi A Nout, Elzbieta M van der Steen-Banasik, Stephanie M de Boer, Melanie E Powell, Naveena Singh, Linda R Mileshkin, Helen J Mackay, Alexandra Leary, Hans W Nijman, Vincent THBM Smit, et al.

Journal article  |  2023  |  Lancet Digit Health

BACKGROUND: Endometrial cancer can be molecularly classified into POLEmut, mismatch repair deficient (MMRd), p53 abnormal (p53abn)..

Prognostic significance of FIGO 2018 staging of loco-regionally advanced cervical cancer (LRACC) with the use of MRI and PET and implications for treatment selection.

Ming Yin Lin, Linda Mileshkin, Orla McNally, Srinivas Kondalsamy-Chennakesavan, Kailash Narayan

Journal article  |  2023  |  Gynecol Oncol

INTRODUCTION: The FIGO 2018 staging of cervix cancer recognizes a total of 11 categories of loco-regionally advanced cervix cancer..

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.

Lisa Vermij, Jan J Jobsen, Alicia León-Castillo, Mariel Brinkhuis, Suzan Roothaan, Melanie E Powell, Stephanie M de Boer, Pearly Khaw, Linda R Mileshkin, Anthony Fyles, Alexandra Leary, Catherine Genestie, Ina M Jürgenliemk-Schulz, Emma J Crosbie, Helen J Mackay, Hans W Nijman, Remi A Nout, Vincent THBM Smit, Carien L Creutzberg, Nanda Horeweg, et al.

Journal article  |  2023  |  Br J Cancer

BACKGROUND: Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It is uncle..

Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary

Atara Posner, Tharani Sivakumaran, Andrew Pattison, Dariush Etemadmoghadam, Niko Thio, Colin Wood, Krista Fisher, Samantha Webb, Anna DeFazio, Nicholas Wilcken, Bo Gao, Christos S Karapetis, Madhu Singh, Ian M Collins, Gary Richardson, Christopher Steer, Mark Warren, Narayan Karanth, Andrew Fellowes, Stephen B Fox, et al.

Journal article  |  2023  |  JOURNAL FOR IMMUNOTHERAPY OF CANCER

BACKGROUND: Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) ..

Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA).

Deborah Smith, Kristy P Robledo, Sonia Yip, Michelle M Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, Amanda B Spurdle, John Andrews, Martin R Stockler, Linda Mileshkin, Yoland Antill, undefined Australia New Zealand Gynaecological Oncology Group (ANZGOG)

Journal article  |  2022  |  Cancers (Basel)

Women with advanced endometrial carcinoma (EC) with mismatch repair (MMR) deficiency have improved outcomes when treated with immu..